Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 10/2018

01-10-2018 | Original Contributions

The Impact of Obesity and Metabolic Surgery on Chronic Inflammation

Authors: Sonja Chiappetta, Hannah M. Schaack, Bettina Wölnerhannsen, Christine Stier, Simone Squillante, Rudolf A. Weiner

Published in: Obesity Surgery | Issue 10/2018

Login to get access

Abstract

Background

Obesity and metabolic surgery is known to improve chronic inflammatory status. Whether improvement is related to anatomical changes or weight loss is still to debate.

Objective

The aim of this clinical trial is to compare the different bariatric procedures sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and One-anastomosis gastric bypass (OAGB), pertaining to their effects on inflammation markers.

Methods

Patients who underwent SG, RYGB, or OAGB as a primary treatment for severe obesity were included. The data collected preoperatively (T0) and 1, 3, and 6 (T6) months after surgery included gender, weight, comorbidities and toxic habits at baseline, body mass index (BMI), waist circumference, total body weight loss in % (TBWL), leukocyte count in × 103/μl, C-reactive protein (CRP) in mg/l, HbA1c in %, aspartate transaminase in U/l, alanine transaminase in U/l, gamma-glutamyltransferase in U/l, bilirubin in mg/dl, cholesterol in mg/dl, and triglycerides in mg/dl.

Results

Four hundred sixty-eight patients were included. Drop-out rate was 25.8% at T6. Preoperatively the mean value of leukocytes and CRP was 7.4 × 103/μl ± 2 and 10.5 mg/l ± 8.1. At T6, mean value of leukocytes and CRP was 7.1 × 103/μl ± 1.9 (p = 0.075) and 7.2 mg/l ± 9.5 (p < 0.001). TBWL % at T6 was 24.2 ± 7.6 in the SG, 25.8 ± 5.9 in the RYGB and 25.5 ± 4.6 in the OAGB group. Comparing SG, RYGB, and OAGB in relation to leukocyte count and CRP no significant difference was seen between the groups.

Conclusion

CRP but not leukocyte count decreased after all three bariatric procedures but without any significance between the three groups. Surgically induced weight loss and not anatomical changes might play an important role for improvement in chronic inflammation.

Trial Registration

The National Clinical Trials number was NCT02697695 (https://​clinicaltrials.​gov/​ct2/​show/​NCT02697695).
Literature
1.
Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature. 2017;542(7640):177–85.CrossRefPubMed
2.
3.
4.
5.
Dahlman I, Elsen M, Tennagels N, et al. Functional annotation of the human fat cell secretome. Arch Physiol Biochem. 2012;118(3):84–91.CrossRefPubMed
6.
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.CrossRefPubMed
7.
Krinninger P, Ensenauer R, Ehlers K, et al. Peripheral monocytes of obese women display increased chemokine receptor expression and migration capacity. J Clin Endocrinol Metab. 2014;99(7):2500–9.CrossRefPubMed
8.
Bochud M, Marquant F, Marques-Vidal PM, et al. Association between C-reactive protein and adiposity in women. J Clin Endocrinol Metab. 2009;94(10):3969–77.CrossRefPubMed
9.
Shemesh T, Rowley KG, Jenkins A, et al. Differential association of C-reactive protein with adiposity in men and women in an aboriginal community in Northeast Arnhem Land of Australia. Int J Obes. 2007;31(1):103–8.CrossRef
10.
11.
Hanusch-Enserer U, Cauza E, Spak M, et al. Acute-phase response and immunological markers in morbid obese patients and patients following adjustable gastric banding. Int J Obes Relat Metab Disord. 2003;27(3):355–61.CrossRefPubMed
12.
Netto BD, Bettini SC, Clemente AP, et al. Roux-en-Y gastric bypass decreases pro-inflammatory and thrombotic biomarkers in individuals with extreme obesity. Obes Surg. 2015;25(6):1010–8.CrossRefPubMed
13.
Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (atherosclerosis risk in communities study): a cohort study. Lancet. 1999;353(9165):1649–52.CrossRefPubMed
14.
van Wijk DF, Boekholdt SM, Arsenault BJ, Ahmadi-Abhari S, Wareham NJ, Stroes ES, et al. C-reactive protein identifies low-risk metabolically healthy obese persons: the European prospective investigation of Cancer-Norfolk Prospective Population Study. J Am Heart Assoc 2016;5(6).
15.
Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351(26):2683–93.CrossRefPubMed
16.
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386(9997):964–73.CrossRefPubMed
17.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–51.CrossRefPubMedPubMedCentral
18.
van Dielen FM, Buurman WA, Hadfoune M, et al. Macrophage inhibitory factor, plasminogen activator inhibitor-1, other acute phase proteins, and inflammatory mediators normalize as a result of weight loss in morbidly obese subjects treated with gastric restrictive surgery. J Clin Endocrinol Metab. 2004;89(8):4062–8.CrossRefPubMed
19.
Santos J, Salgado P, Santos C, et al. Effect of bariatric surgery on weight loss, inflammation, iron metabolism, and lipid profile. Scand J Surg. 2014;103(1):21–5.CrossRefPubMed
20.
Cottam DR, Schaefer PA, Shaftan GW, et al. Effect of surgically-induced weight loss on leukocyte indicators of chronic inflammation in morbid obesity. Obes Surg. 2002;12(3):335–42.CrossRefPubMed
21.
Park S, Kim YJ, Choi CY, et al. Bariatric surgery can reduce albuminuria in patients with severe obesity and normal kidney function by reducing systemic inflammation. Obes Surg. 2018;28(3):831–7.CrossRefPubMed
22.
Pontiroli AE, Frige F, Paganelli M, et al. In morbid obesity, metabolic abnormalities and adhesion molecules correlate with visceral fat, not with subcutaneous fat: effect of weight loss through surgery. Obes Surg. 2009;19(6):745–50.CrossRefPubMed
23.
Rao SR. Inflammatory markers and bariatric surgery: a meta-analysis. Inflamm Res. 2012;61(8):789–807.CrossRefPubMed
24.
Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes. 2009;33(Suppl 1):S33–40.CrossRef
25.
Billeter AT, Senft J, Gotthardt D, et al. Combined non-alcoholic fatty liver disease and type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass?—a controlled matched pair study of 34 patients. Obes Surg. 2016;26(8):1867–74.CrossRefPubMed
26.
Patterson RE, Sears DD. Metabolic effects of intermittent fasting. Annu Rev Nutr. 2017;37:371–93.CrossRefPubMed
27.
Marathe PH, Gao HX, Close KL. American Diabetes Association Standards of Medical Care in Diabetes 2017. J Diabetes. 2017;9(4):320–4.CrossRefPubMed
28.
Chiappetta S, Stier C, Squillante S, et al. The importance of the Edmonton Obesity Staging System in predicting postoperative outcome and 30-day mortality after metabolic surgery. Surg Obes Relat Dis. 2016;12(10):1847–55.CrossRefPubMed
29.
Guidelines for reporting results in bariatric surgery. Standards Committee, American Society for Bariatric Surgery. Obes Surg. 1997;7(6):521–2.CrossRef
30.
Nijhuis J, van Dielen FM, Fouraschen SM, et al. Endothelial activation markers and their key regulators after restrictive bariatric surgery. Obesity (Silver Spring). 2007;15(6):1395–9.CrossRef
31.
Pekala P, Kawakami M, Vine W, et al. Studies of insulin resistance in adipocytes induced by macrophage mediator. J Exp Med. 1983;157(4):1360–5.CrossRefPubMed
32.
Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39(6):861–77.CrossRefPubMed
33.
De Luca M, Angrisani L, Himpens J, et al. Indications for surgery for obesity and weight-related diseases: position statements from the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO). Obes Surg. 2016;26(8):1659–96.CrossRefPubMedPubMedCentral
34.
Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Surg Obes Relat Dis. 2016;12(6):1144–62.CrossRefPubMed
35.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–256.e5.CrossRefPubMed
36.
Afshar S, Malcomson F, Kelly SB, Seymour K, Woodcock S, Mathers JC. Biomarkers of colorectal cancer risk decrease 6 months after Roux-en-Y gastric bypass surgery. Obes Surg 2017.
37.
Illan-Gomez F, Gonzalvez-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950–5.CrossRefPubMed
38.
39.
Yadav R, Hama S, Liu Y, et al. Effect of roux-en-Y bariatric surgery on lipoproteins, insulin resistance, and systemic and vascular inflammation in obesity and diabetes. Front Immunol. 2017;8:1512.CrossRefPubMedPubMedCentral
40.
Dixon JB, O'Brien PE. Obesity and the white blood cell count: changes with sustained weight loss. Obes Surg. 2006;16(3):251–7.CrossRefPubMed
41.
Thorand B, Baumert J, Doring A, et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis. 2006;184(1):216–24.CrossRefPubMed
42.
Kassi E, Spilioti E, Nasiri-Ansari N, et al. Vascular inflammation and atherosclerosis: the role of estrogen receptors. Curr Med Chem. 2015;22(22):2651–65.CrossRefPubMed
43.
Fenske WK, Dubb S, Bueter M, et al. Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study. Surg Obes Relat Dis. 2013;9(4):559–68.CrossRefPubMed
44.
Iannelli A, Anty R, Schneck AS, et al. Inflammation, insulin resistance, lipid disturbances, anthropometrics, and metabolic syndrome in morbidly obese patients: a case control study comparing laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy. Surgery. 2011;149(3):364–70.CrossRefPubMed
45.
Lips MA, van Klinken JB, Pijl H, et al. Weight loss induced by very low calorie diet is associated with a more beneficial systemic inflammatory profile than by Roux-en-Y gastric bypass. Metabolism. 2016;65(11):1614–20.CrossRefPubMed
46.
Brandhorst S, Choi IY, Wei M, et al. A periodic diet that mimics fasting promotes multi-system regeneration, enhanced cognitive performance, and health span. Cell Metab. 2015;22(1):86–99.CrossRefPubMedPubMedCentral
47.
Gill RS, Karmali S, Sharma AM. The potential role of the Edmonton obesity staging system in determining indications for bariatric surgery. Obes Surg. 2011;21(12):1947–9.CrossRefPubMed
48.
Casimiro Perez JA, Fernandez Quesada C, Del Val Groba Marco M, et al. Obesity Surgery Score (OSS) for prioritization in the bariatric surgery waiting list: a need of public health systems and a literature review. Obes Surg. 2018;28(4):1175–84.CrossRefPubMed
49.
Iyengar NM, Gucalp A, Dannenberg AJ, et al. Obesity and cancer mechanisms: tumor microenvironment and inflammation. J Clin Oncol. 2016;34(35):4270–6.CrossRefPubMedPubMedCentral
Metadata
Title
The Impact of Obesity and Metabolic Surgery on Chronic Inflammation
Authors
Sonja Chiappetta
Hannah M. Schaack
Bettina Wölnerhannsen
Christine Stier
Simone Squillante
Rudolf A. Weiner
Publication date
01-10-2018
Publisher
Springer US
Published in
Obesity Surgery / Issue 10/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-018-3320-y

Other articles of this Issue 10/2018

Obesity Surgery 10/2018 Go to the issue

New Concept

Effective Implementation of Peri-operative Local Guidelines for Metabolic Surgery in Patients with Diabetes Mellitus in a Tier 4 Setting Demonstrate Improved Work Efficiency and Resource Allocation

Original Contributions

Mid-term 4-Year Outcomes with Single Anastomosis Duodenal-Ileal Bypass with Sleeve Gastrectomy Surgery at a Single US Center

Original Contributions

Microcirculatory Improvement Induced by Laparoscopic Sleeve Gastrectomy Is Related to Insulin Sensitivity Retrieval

Review Article

Does Body Contouring After Bariatric Weight Loss Enhance Quality of Life? A Systematic Review of QOL Studies

Original Contributions

Selection of Bypass vs Sleeve for the Management of Type-2 Diabetes in Severely Obese: Could Ethnicity Play a Role?

Original Contributions

Change in Children’s Self-Concept, Body-Esteem, and Eating Attitudes Before and 4 Years After Maternal RYGB